RETATRUTIDE 20MG

Retatrutide is a next-generation triple agonist peptide that targets the GLP-1, GIP and glucagon receptor pathways simultaneously. This advanced three-pathway mechanism sets it apart from single-agonist peptides such as Semaglutide and dual-agonist peptides such as Tirzepatide.

By engaging all three metabolic pathways at once, Retatrutide offers a comprehensive research profile related to appetite regulation, energy expenditure, fat metabolism, glycemic control and insulin sensitivity. Its combined action on appetite signalling and energy utilization has made it one of the most sought-after compounds in modern metabolic and weight-management research.

Clinical research has reported significant body-weight reductions alongside improvements in several markers of metabolic health. Retatrutide’s ability to combine appetite control, increased energy expenditure and enhanced metabolic efficiency gives it significant potential for advanced research involving obesity, glucose regulation and cardiovascular health.

Supplied as a high-purity lyophilized powder, Retatrutide 10 mg is formulated to support precise, consistent and reliable laboratory research.

Form: Lyophilized peptide powder
Contents: 10 mg per vial
Purity: ≥99%
Testing: Meticulously tested for identity, purity and consistency
Storage: Keep in a cool, dry environment; refrigerate at 2°C–8°C after reconstitution
Intended use: For laboratory research purposes only. Not for human or veterinary use.